In an apparent case of first impression, a Philadelphia judge has ruled that two pharmaceutical companies may have a legal duty to class members for money spent on the generic version of the companies' name-brand drug allegedly marketed by the companies for uses not approved by federal regulators. The generic drug in the case was produced by a third-party manufacturer.
Drug Companies on the Hook for Off-Label Use of Generic
The Legal Intelligencer
March 24, 2008